Pomegranate extract
CAS 84961-57-9
Pomegranate extract (CAS 84961-57-9) is a pharmaceutical compound with 0 bioactivity targets and 18 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Pomegranate extract is linked to DTXSID801018375 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Pomegranate extract used for in pharmaceutical contexts?
Pomegranate extract (CAS 84961-57-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Pomegranate extract?
Pomegranate extract has 18 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Asthma, Bronchitis, Death, Diabetes mellitus, Dyspnoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Pomegranate extract also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Pomegranate Extract (Punica Granatum Extract) with EU status "permitted".
What clinical phase is Pomegranate extract in?
No phase 1-4 clinical development badge is rendered for Pomegranate extract because the matched compound identifier rows do not contain a max-phase value.